Nautilus Biotechnology Ownership
| NAUT Stock | USD 0.99 0.01 1.00% |
Shares in Circulation | First Issued 2018-12-31 | Previous Quarter 125.5 M | Current Value 125.8 M | Avarage Shares Outstanding 85.1 M | Quarterly Volatility 54.3 M |
Nautilus |
Nautilus Stock Ownership Analysis
About 33.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.6. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nautilus Biotechnology recorded a loss per share of 0.56. The entity had not issued any dividends in recent years. Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington. Nautilus Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To find out more about Nautilus Biotechnology contact Sujal Patel at 206 333 2001 or learn more at https://www.nautilus.bio.Besides selling stocks to institutional investors, Nautilus Biotechnology also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Nautilus Biotechnology's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Nautilus Biotechnology's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Nautilus Biotechnology Quarterly Liabilities And Stockholders Equity |
|
About 33.0% of Nautilus Biotechnology are currently held by insiders. Unlike Nautilus Biotechnology's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Nautilus Biotechnology's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Nautilus Biotechnology's insider trades
Nautilus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Nautilus Biotechnology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Nautilus Biotechnology backward and forwards among themselves. Nautilus Biotechnology's institutional investor refers to the entity that pools money to purchase Nautilus Biotechnology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tikvah Management Llc | 2024-12-31 | 726.9 K | Clarius Group, Llc | 2024-12-31 | 636.5 K | Botty Investors Llc | 2024-12-31 | 606.1 K | Northern Trust Corp | 2024-12-31 | 474.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 393.6 K | Wexford Capital Lp | 2024-12-31 | 325.2 K | Sentinel Trust Co Lba | 2024-12-31 | 255 K | Alyeska Investment Group, L.p. | 2024-12-31 | 253.5 K | Renaissance Technologies Corp | 2024-12-31 | 250.2 K | Perceptive Advisors Llc | 2024-12-31 | 12.6 M | Cercano Management Llc | 2024-12-31 | 7.2 M |
Nautilus Biotechnology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nautilus Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nautilus Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nautilus Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nautilus Biotechnology Outstanding Bonds
Nautilus Biotechnology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Nautilus Biotechnology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Nautilus bonds can be classified according to their maturity, which is the date when Nautilus Biotechnology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| NWG 16 29 SEP 26 Corp BondUS63906YAD04 | View | |
| NWG 5516 30 SEP 28 Corp BondUS639057AF59 | View | |
| NWG 46 Corp BondUS639057AD02 | View | |
| NATWEST GROUP PLC Corp BondUS639057AC29 | View | |
| NWG 5847 02 MAR 27 Corp BondUS639057AJ71 | View | |
| NWG 5903249 22 MAR 25 Corp BondUS63906YAF51 | View | |
| NWG 3479 22 MAR 25 Corp BondUS63906YAG35 | View | |
| NWG 6016 02 MAR 34 Corp BondUS639057AH16 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.